{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:42:58Z","timestamp":1788190978488,"version":"build-2803163510"},"reference-count":41,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ipsen Biopharmaceuticals Canada, Inc., Mississauga, ON, Canada","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Cervical dystonia (CD) is a neurological movement disorder characterized by sustained involuntary muscle contractions. First-line therapy for CD is intramuscular injections of botulinum neurotoxin (e.g., abobotulinumtoxinA) into the affected muscles. The objective of this systematic literature review is to assess the clinical evidence regarding the effects of abobotulinumtoxinA for treatment of CD in studies of safety, efficacy, patient-reported outcomes, and economic outcomes. Using comprehensive electronic medical literature databases, a search strategy was developed using a combination of Medical Subject Heading terms and keywords. Results were reviewed by two independent reviewers who rated the level of evidence. The search yielded 263 publications, of which 232 were excluded for being duplicate publications, not meeting the selection criteria, or failing to meet predefined eligibility criteria, leaving a total of 31 articles. Clinical efficacy, patient-reported outcomes, and safety data were in 6 placebo-controlled trials (8 articles), 6 active-controlled trials, and 16 observational studies (17 articles). Data on health economic outcomes were provided in one of the clinical trials, in two of the observational studies, and in one specific cost-analysis publication. This review demonstrated that the routine use of abobotulinumtoxinA in CD is well-established, effective, and generally well-tolerated, with a relatively low cost of treatment.<\/jats:p>","DOI":"10.3390\/toxins12080470","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T09:06:09Z","timestamp":1595581569000},"page":"470","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-0180","authenticated-orcid":false,"given":"Alfonso","family":"Fasano","sequence":"first","affiliation":[{"name":"Edmond J. Safra Program in Parkinson\u2019s Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, ON M5T2S8, Canada"},{"name":"Division of Neurology, University of Toronto, Toronto, ON M5S 3H2, Canada"},{"name":"Krembil Brain Institute, Toronto, ON M5T 1M8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1197-5308","authenticated-orcid":false,"given":"Vijayashankar","family":"Paramanandam","sequence":"additional","affiliation":[{"name":"Edmond J. Safra Program in Parkinson\u2019s Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, ON M5T2S8, Canada"},{"name":"Division of Neurology, University of Toronto, Toronto, ON M5S 3H2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandar","family":"Jog","sequence":"additional","affiliation":[{"name":"Lawson Health Research Institute, London, ON N6A 4V2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/mds.25567","article-title":"The focal dystonias: Current views and challenges for future research","volume":"28","author":"Jinnah","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_2","first-page":"tre-03-193-4374-4372","article-title":"Descriptive epidemiology of cervical dystonia","volume":"3","author":"Defazio","year":"2013","journal-title":"Tremor Other Hyperkinet. Mov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00415-015-7703-x","article-title":"Practical guidance for CD management involving treatment of botulinum toxin: A consensus statement","volume":"262","author":"Albanese","year":"2015","journal-title":"J. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P., Clarke, M., Devereaux, P.J., Kleijnen, J., and Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med., 6.","DOI":"10.2427\/5768"},{"key":"ref_6","unstructured":"Sch\u00fcnemann, H., Oxman, A., Vist, G., Higgins, J., Deeks, J., and Glasziou, G. (2020, July 11). Interpreting Results and Drawing Conclusions. In Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Available online: https:\/\/handbook-5-1.cochrane.org\/index.htm#chapter_12\/12_interpreting_results_and_drawing_conclusions.htm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","article-title":"What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group","volume":"64","author":"Poewe","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s004150170028","article-title":"Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: Results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study","volume":"248","author":"Wissel","year":"2001","journal-title":"J. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/00207454.2017.1406935","article-title":"A 500 U\/2 mL dilution of abobotulinumtoxinA vs. placebo: Randomized study in cervical dystonia","volume":"128","author":"Lew","year":"2018","journal-title":"Int. J. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/mds.26760","article-title":"Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial","volume":"31","author":"Poewe","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","article-title":"Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia","volume":"16","author":"Truong","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.baga.2014.04.004","article-title":"Improvement of SF-36 scores in cervical dystonia patients\u2014Is there a treatment effect when evaluating subscales?","volume":"4","author":"Jen","year":"2014","journal-title":"Basal Ganglia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e005150","DOI":"10.1136\/bmjopen-2014-005150","article-title":"Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): Results from a randomised, double-blind, placebo-controlled study","volume":"4","author":"Mordin","year":"2014","journal-title":"BMJ Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","article-title":"A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia","volume":"64","author":"Odergren","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000057902","article-title":"Low-dose botulinum toxin-a treatment of cervical dystonia\u2014A double-blind, randomized pilot study","volume":"47","author":"Fries","year":"2002","journal-title":"Eur. Neurol."},{"key":"ref_17","first-page":"459","article-title":"Respective potencies of Botox and Dysport: A double blind, randomised, crossover study in cervical dystonia","volume":"72","author":"Ranoux","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/mds.26085","article-title":"Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: A double-blind, randomized study","volume":"30","author":"Yun","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/WNF.0000000000000107","article-title":"Comparison between Dysport and Prosigne in the treatment of cervical dystonia","volume":"38","author":"Barbosa","year":"2015","journal-title":"Clin. Neuropharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/exnr.2000.7583","article-title":"Botulinum A toxin: Dysport improvement of biological availability","volume":"168","author":"Bigalke","year":"2001","journal-title":"Exp. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mus.880180708","article-title":"Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin","volume":"18","author":"Francart","year":"1995","journal-title":"Muscle Nerve"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","article-title":"Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency. German Dystonia Study Group","volume":"246","author":"Kessler","year":"1999","journal-title":"J. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1468-1331.1997.tb00382.x","article-title":"Long-term follow-up by video of cervical dystonia treated with botulinum toxin","volume":"4","author":"Jamieson","year":"1997","journal-title":"Eur. J. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hefter, H., Benecke, R., Erbguth, F., Jost, W., Reichel, G., and Wissel, J. (2013). An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport). BMJ Open, 3.","DOI":"10.1136\/bmjopen-2012-001853"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e000196","DOI":"10.1136\/bmjopen-2011-000196","article-title":"A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis","volume":"1","author":"Hefter","year":"2011","journal-title":"BMJ Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00002826-200007000-00006","article-title":"A pharmacoeconomic evaluation of botulinum toxin in the treatment of spasmodic torticollis","volume":"23","author":"More","year":"2000","journal-title":"Clin. Neuropharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Misra, V.P., Ehler, E., Zakine, B., Maisonobe, P., and Simonetta-Moreau, M. (2012). Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: Results from an international observational study. BMJ Open, 2.","DOI":"10.1136\/bmjopen-2012-000881"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2017.02.042","article-title":"Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry","volume":"376","author":"Trosch","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12640-017-9737-6","article-title":"Long-Term Abobotulinumtoxin a treatment of cervical dystonia","volume":"32","author":"Bentivoglio","year":"2017","journal-title":"Neurotox. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00702-013-1127-5","article-title":"Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: A retrospective analysis","volume":"121","author":"Hefter","year":"2014","journal-title":"J. Neural Transm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00019053-199712060-00009","article-title":"Costs of treating dystonias and hemifacial spasm with botulinum toxin A","volume":"12","author":"Dodel","year":"1997","journal-title":"Pharmacoeconomics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00002826-199702000-00005","article-title":"Quantitative electromyography-guided botulinum toxin treatment of cervical dystonia","volume":"20","author":"Finsterer","year":"1997","journal-title":"Clin. Neuropharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1179\/174313209X405137","article-title":"A long-term follow-up of botulinum toxin A in cervical dystonia","volume":"31","author":"Mohammadi","year":"2009","journal-title":"Neurol. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10659","article-title":"Long-term follow-up of cervical dystonia patients treated with botulinum toxin A","volume":"19","author":"Haussermann","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/mds.20468","article-title":"Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study","volume":"20","author":"Marchetti","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/WNF.0b013e3182711fc0","article-title":"Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia","volume":"35","author":"Rystedt","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3109\/00207454.2012.665971","article-title":"A 17-year experience of abobotulinumtoxina in cervical dystonia","volume":"122","year":"2012","journal-title":"Int. J. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00702-012-0887-7","article-title":"Rating scales for cervical dystonia: A critical evaluation of tools for outcome assessment of botulinum toxin therapy","volume":"120","author":"Jost","year":"2013","journal-title":"J. Neural Transm. (Vienna)"},{"key":"ref_39","first-page":"445","article-title":"The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): Assessment of validity and inter-rater reliability (abstract)","volume":"40","author":"Consky","year":"1990","journal-title":"Neurology"},{"key":"ref_40","first-page":"854","article-title":"A retrospective, single-center comparative cost analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for cervical dystonia treatment","volume":"21","author":"Trosch","year":"2015","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/CEOR.S112254","article-title":"Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom","volume":"9","author":"Muthukumar","year":"2017","journal-title":"Clinicoecon. Outcomes Res."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/8\/470\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:51:25Z","timestamp":1760176285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/8\/470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["toxins12080470"],"URL":"https:\/\/doi.org\/10.3390\/toxins12080470","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]}}}